Evidence map›Paper›PMID 40633129›Full record

ArticleVaccine2025

IFITM3-deficient mice as a model for testing influenza virus vaccines via the intramuscular route.

Adrian C Eddy, Samuel Speaks, Megan Roth, Jack E Roettger, Brendan M Reznik, Shreenath Mohan, Ben D Liu, Emily A Hemann, Jacob S Yount

Abstract read
In one paragraph

Article in Vaccine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Adrian C EddyDepartment of Microbial infection and Immunity, The Ohio State University, Columbus, OH 43210, USA.
Samuel SpeaksDepartment of Microbial infection and Immunity, The Ohio State University, Columbus, OH 43210, USA.
Megan RothDepartment of Microbial infection and Immunity, The Ohio State University, Columbus, OH 43210, USA.
Jack E RoettgerDepartment of Microbial infection and Immunity, The Ohio State University, Columbus, OH 43210, USA.
Brendan M ReznikDepartment of Microbial infection and Immunity, The Ohio State University, Columbus, OH 43210, USA.
Shreenath MohanDepartment of Microbial infection and Immunity, The Ohio State University, Columbus, OH 43210, USA.
Ben D LiuDepartment of Microbial infection and Immunity, The Ohio State University, Columbus, OH 43210, USA.
Emily A HemannDepartment of Microbial infection and Immunity, The Ohio State University, Columbus, OH 43210, USA. Electronic address: Emily.Hemann@osumc.edu.
Jacob S YountDepartment of Microbial infection and Immunity, The Ohio State University, Columbus, OH 43210, USA. Electronic address: Jacob.Yount@osumc.edu.

Funding

Mechanisms of innate resistance to virus infectionsR01AI130110 · NIAID · OHIO STATE UNIVERSITY · PI Jacob Yount · 2017 to 2026
$4.3M
Mechanisms of lung and cardiac pathology in SARS-CoV-2 infectionsR01HL168501 · NHLBI · OHIO STATE UNIVERSITY · PI Amal O Amer, Jacob Yount · 2023 to 2026
$2.9M
Protein therapy to treat virus induced cardiopulmonary injuryR01HL157215 · NHLBI · UNIVERSITY OF VIRGINIA · PI CAI, CHUANXI, MA, JIANJIE · 2022 to 2025
$2.7M
Mechanistic characterization of a new master regulator of cardiac virus infectionsR01HL154001 · NHLBI · OHIO STATE UNIVERSITY · PI ACCORNERO, FEDERICA, YOUNT, JACOB · 2020 to 2023
$2.3M
RIG-I-like receptor regulation of pulmonary inflammation and homeostasisR35GM150503 · NIGMS · OHIO STATE UNIVERSITY · PI Emily Ann Hemann · 2023 to 2026
$1.6M
NON-CANONICAL MECHANISMS FOR INTERFERON-LAMBDA REGULATION OF SARS-COV-2 INFECTIONR21AI174050 · NIAID · OHIO STATE UNIVERSITY · PI HEMANN, EMILY ANN · 2023 to 2024
$413k
Establishing a relevant mouse model with susceptibility to non-adapted influenza viruses for vaccine challenge studiesR21AI151230 · NIAID · OHIO STATE UNIVERSITY · PI YOUNT, JACOB · 2020 to 2021
$409k
NHLBI NIH HHS R01 HL154001NHLBI NIH HHS R01 HL157215NHLBI NIH HHS R01 HL168501NIAID NIH HHS R01 AI130110NIAID NIH HHS R21 AI151230NIAID NIH HHS R21 AI174050NIGMS NIH HHS R35 GM150503
6 · The paper itself

Abstract

Influenza virus infections remain a significant global health concern. Development of a universal influenza vaccine has been met with challenges, in part due to difficulties with preclinical vaccine testing in mice, which are widely available but are often poorly infected with human and avian influenza viruses. Here, we investigate whether mice lacking interferon-induced transmembrane protein 3 (IFITM3), an antiviral restriction factor, provide a suitable preclinical model for vaccine testing since we observe enhanced replication of multiple influenza virus strains in these mice. We find that IFITM3 KO mice produce a blunted antibody response to intramuscular vaccination that is increased by a booster dose. Nonetheless, their adaptive immune responses to previous infections and vaccinations were found to be functional in limiting weight loss, survival, and viral replication in challenge studies. Overall, our findings identify IFITM3 KO mice as an accessible, functionally immunocompetent preclinical model for assessment of influenza vaccines.

Indexed as

Influenza VaccinesMembrane ProteinsOrthomyxoviridae InfectionsRNA-Binding ProteinsAdaptive ImmunityAnimalsAntibodies, ViralDisease Models, AnimalFemaleInjections, IntramuscularMiceMice, Inbred C57BLMice, KnockoutVaccinationVirus ReplicationAntibodies, Viralfragilis protein, mouseInfluenza VaccinesMembrane ProteinsRNA-Binding ProteinsIFITM3InfluenzaMouse modelVaccine

Identifiers

PMID40633129
PMCPMC12780940

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.